<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2019-07-08 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, we, or the Agency) is announcing the availability of an immediately in effect guidance for industry entitled "Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency." This guidance describes FDA's policy concerning the conditions under which the Agency does not generally intend to take regulatory action against a licensed pharmacist in a State-licensed pharmacy or Federal fac...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Rule</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2019-14355</p>
    <p><strong>Publication Date:</strong> 2019-07-08</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2019/07/08/2019-14355/compliance-policy-for-certain-compounding-of-oral-oxitriptan-5-htp-drug-products-for-patients-with">https://www.federalregister.gov/documents/2019/07/08/2019-14355/compliance-policy-for-certain-compounding-of-oral-oxitriptan-5-htp-drug-products-for-patients-with</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2019-14355</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
